Urology News and Research

Latest Urology News and Research

New surgical method preserves long-term renal function following removal of renal tumours

Renal cell carcinomas are one of the most common types of cancer. In order to preserve its wide range of functions, every effort is made not to remove the entire kidney, but rather just a portion of it. A surgical method that preserves long-term renal function has now been carried out successfully for the first time in the Department of Urology at the MedUni Vienna and Vienna General Hospital.

13 Jul 2015

Revised work hour restrictions for resident physicians fail to improve surgical patient outcomes

Work hour restrictions for resident physicians, revised nationally four years ago largely to protect patients against physician trainees' fatigue-related errors, have not had the desired effect of lowering postoperative complication rates in several common surgical specialties, according to new study results.

9 Jul 2015

Study examines recent trends in community-based practices to improve management of localized prostate cancer

After years of overtreatment for patients with low-risk prostate cancer, rates of active surveillance/ watchful waiting increased sharply in 2010 through 2013, and high-risk disease was more often treated appropriately with potentially curative local treatment rather than androgen deprivation alone, according to a study in the July 7 issue of JAMA.

8 Jul 2015

Aytu BioScience now trading under new symbol following its corporate name change

Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that the company is now trading under the new symbol "AYTU," following its corporate name change, which became effective June 8, 2015.

7 Jul 2015

Allergan agrees to acquire exclusive worldwide rights to Merck's CGRP migraine development program

Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).

7 Jul 2015

Study focuses on health risks from exposure to air pollution near roads and freeways

Policymakers and developers planning high-density housing near public transit with the goal of reducing automobile use and greenhouse gas emissions that contribute to global warming need a clearer understanding of the health risks from air pollution that may be created if that housing is also built near busy roads and freeways, according to new research by Keck School of Medicine of the University of Southern California scientists.

7 Jul 2015

Expectant management remains underused for men with low-risk prostate cancer

Monitoring men with very low- and low-risk prostate cancers using watchful waiting or active surveillance, called expectant management, is a useful approach for a large number of men with localized tumors and could spare them the debilitating side effects of aggressive treatments that are too often unnecessarily used in this patient population, a UCLA review of common practices in prostate cancer has found.

7 Jul 2015

Allergan enters into agreement to acquire Oculeve

Allergan plc, a leading global pharmaceutical company, and Oculeve, a development-stage medical device company focused on developing novel treatments for dry eye disease, today announced that they have entered into an agreement under which Allergan will acquire Oculeve in an all-cash transaction.

6 Jul 2015

Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

America's oldest cancer center and one of the world's newest oncology centers are partnering to improve access to cancer prevention, screening and care for the people of Nigeria. Roswell Park Cancer Institute and Lakeshore Cancer Center have announced an affiliation that will see Roswell Park faculty providing clinical consultations to assist LCC oncologists, who will also have access to both training at RPCI and continuing professional education seminars they can participate in remotely.

1 Jul 2015

Telesta submits Biologics License Application for MCNA to FDA

Telesta Therapeutics Inc. announced today that it has submitted electronically, through its U.S. agent, a Biologics License Application (BLA) to the United States Food and Drug Administration for MCNA. MCNA is Telesta's novel biologic immunotherapeutic for the treatment of high-risk non-muscle invasive bladder cancer patients who have failed first-line BCG therapy.

30 Jun 2015

Drugs used against impotence does not increase risk of malignant melanoma

Using drugs for impotence does not increase the risk of malignant melanoma, researchers from Umeå University in Sweden conclude in a publication in JAMA, a top US medical journal. These results contradict previous research indicating such an association.

23 Jun 2015

Bariatric surgery can significantly reduce urinary incontinence

For severely obese people, bariatric surgery may have a benefit besides dramatic weight loss: it can also substantially reduce urinary incontinence.

23 Jun 2015

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Minimally Invasive Urology Institute at The Miriam Hospital is offering UroLift as one of the newest surgical treatments available for men with benign prostatic hyperplasia (BPH), an enlarged prostate condition.

23 Jun 2015

International study provides evidence of clear link between smoking and risk of prostate cancer

Smoking is a known risk factor for the development of various forms of cancer. However, when it comes to the link between smoking and prostate cancer, the findings of previous studies have been contradictory. Now, for the first time, an international study led by MedUni Vienna and Basle University Hospital, has provided evidence of a clear link.

22 Jun 2015

Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the U.S. declined 28 percent in the year following the draft recommendation from the United States Preventive Services Task Force against routine PSA screening for men.

19 Jun 2015

Simple test could help identify genetically inherited risk for prostate cancer

Men with an elevated, genetically inherited risk for prostate cancer could be routinely identified with a simple blood or urine test, scientists at UC San Francisco and Kaiser Permanente Northern California have concluded, potentially paving the way to better or earlier diagnosis.

18 Jun 2015

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.

17 Jun 2015

Samadi Robotics Foundation gets donation to find cure for prostate cancer

World renowned robotic prostate cancer surgeon, Dr. David B. Samadi, was awarded the Peter Latos Prostate Cancer Foundation Award last Thursday at the Foundation's 2nd Annual Gala where he was honored in recognition of his faithful service for the treatment, prevention and innovation in the fight against prostate cancer.

16 Jun 2015

Study highlights discovery of genetic variants linked to mucinous ovarian carcinomas

New research by an international team including Keck Medicine of USC scientists is bringing the origins of ovarian cancer into sharper focus.

16 Jun 2015

Actavis adopts Allergan as its new global name

Actavis plc announced that the company has adopted Allergan plc as its new global name and will begin trading today under a new symbol — AGN — after ringing The Opening Bell at the New York Stock Exchange.

15 Jun 2015

Urology News and Research

Latest Urology News and Research

New surgical method preserves long-term renal function following removal of renal tumours

Revised work hour restrictions for resident physicians fail to improve surgical patient outcomes

Study examines recent trends in community-based practices to improve management of localized prostate cancer

Aytu BioScience now trading under new symbol following its corporate name change

Allergan agrees to acquire exclusive worldwide rights to Merck's CGRP migraine development program

Study focuses on health risks from exposure to air pollution near roads and freeways

Expectant management remains underused for men with low-risk prostate cancer

Allergan enters into agreement to acquire Oculeve

Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

Telesta submits Biologics License Application for MCNA to FDA

Drugs used against impotence does not increase risk of malignant melanoma

Bariatric surgery can significantly reduce urinary incontinence

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

International study provides evidence of clear link between smoking and risk of prostate cancer

Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

Simple test could help identify genetically inherited risk for prostate cancer

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Samadi Robotics Foundation gets donation to find cure for prostate cancer

Study highlights discovery of genetic variants linked to mucinous ovarian carcinomas

Actavis adopts Allergan as its new global name

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Urology News and Research

Latest Urology News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in